Published in Cancer Weekly, June 8th, 2004
Under contract with the NCI, Lynx is applying MPSS to identify chromosome reconfigurations in human cancer. Every cancer has distinctive chromosomal rearrangements that are not present in the normal cells from which it arose. Lynx's patented "di-signature" technology enables the simultaneous characterization of millions of paired DNA fragments, separated by a defined genomic distance, from across the genome.
The fragment pairs...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.